Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

In February 2004, bevacizumab (Avastin; Genentech), an antibody against vascular endothelial growth factor, was approved by the US FDA for the first-line treatment of metastatic colorectal cancer, a leading cause of cancer deaths worldwide. As the first approved agent to target tumour angiogenesis, it now looks set to become a blockbuster, helped by anticipated approvals for other cancer types, including non-small-cell lung cancer and renal cell cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Simplified view of VEGF signalling and tumour angiogenesis.
Figure 2: Market for drugs to treat colorectal cancer in US $ million.

References

  1. Ferrara, N. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391–400 (2004).

    Article  CAS  Google Scholar 

  2. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).

    Article  CAS  PubMed  Google Scholar 

  3. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993).

    Article  CAS  PubMed  Google Scholar 

  4. Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).

    CAS  PubMed  Google Scholar 

  5. Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).

    Article  PubMed  Google Scholar 

  6. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).

    Article  CAS  PubMed  Google Scholar 

  7. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/125085lbl.pdf> (2004).

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

  2. Decision Resources International, 50–51 Russell Square, London, WC1B 4HQ, UK

    Mohamed Muhsin & Joanne Graham

Authors
  1. Mohamed Muhsin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanne Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Muhsin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muhsin, M., Graham, J. & Kirkpatrick, P. Bevacizumab. Nat Rev Drug Discov 3, 995–996 (2004). https://doi.org/10.1038/nrd1601

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1601

  • Springer Nature Limited

This article is cited by

Search

Navigation